Histogenics Corp (HSGX) Given Average Rating of “Buy” by Brokerages

Share on StockTwits

Histogenics Corp (NASDAQ:HSGX) has been assigned a consensus rating of “Buy” from the six research firms that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $3.00.

Several equities analysts have recently weighed in on the company. BTIG Research cut Histogenics from a “buy” rating to a “neutral” rating in a report on Wednesday. HC Wainwright restated a “buy” rating and issued a $2.00 price objective on shares of Histogenics in a report on Wednesday. Brookline Cap M restated a “buy” rating on shares of Histogenics in a report on Wednesday, August 1st. ValuEngine upgraded Histogenics from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Finally, Zacks Investment Research upgraded Histogenics from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Thursday, July 12th.

A number of institutional investors have recently bought and sold shares of the stock. DRW Securities LLC bought a new position in Histogenics during the second quarter worth about $242,000. Renaissance Technologies LLC grew its holdings in Histogenics by 6.1% during the second quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock worth $961,000 after purchasing an additional 22,133 shares during the period. BlackRock Inc. grew its holdings in Histogenics by 72.0% during the second quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 22,927 shares during the period. Sofinnova Ventures Inc bought a new position in Histogenics during the first quarter worth about $5,712,000. Finally, Archon Capital Management LLC bought a new position in Histogenics during the first quarter worth about $639,000. Institutional investors and hedge funds own 45.89% of the company’s stock.

Shares of NASDAQ HSGX traded down $2.01 during mid-day trading on Wednesday, hitting $0.76. The company had a trading volume of 14,524,400 shares, compared to its average volume of 209,284. The stock has a market capitalization of $85.37 million, a price-to-earnings ratio of -0.78 and a beta of 1.69. Histogenics has a one year low of $0.73 and a one year high of $3.35.

Histogenics (NASDAQ:HSGX) last announced its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.10. sell-side analysts anticipate that Histogenics will post -0.71 earnings per share for the current fiscal year.

About Histogenics

Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

See Also: Fiduciary

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply